FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2109833554> ?p ?o ?g. }

• W2109833554 endingPage "772" @default.
• W2109833554 startingPage "767" @default.
• W2109833554 abstract "Purpose There is no effective therapy for patients with distant metastasis of medullary thyroid carcinoma (MTC). Activating mutations in the RET proto-oncogene cause hereditary MTC, which provides a strong therapeutic rationale for targeting RET kinase activity. This open-label, phase II study assessed the efficacy of vandetanib, a selective oral inhibitor of RET, vascular endothelial growth factor receptor, and epidermal growth factor receptor signaling, in patients with advanced hereditary MTC. Methods Patients with unresectable locally advanced or metastatic hereditary MTC received initial treatment with once-daily oral vandetanib 300 mg. The dose was adjusted additionally in some patients on the basis of observed toxicity until disease progression or any other withdrawal criterion was met. The primary assessment was objective tumor response (by RECIST [Response Evaluation Criteria in Solid Tumors]). Results Thirty patients received initial treatment with vandetanib 300 mg/d. On the basis of investigator assessments, 20% of patients (ie, six of 30 patients) experienced a confirmed partial response (median duration of response at data cutoff, 10.2 months). An additional 53% of patients (ie, 16 of 30 patients) experienced stable disease at ≥ 24 weeks, which yielded a disease control rate of 73% (ie, 22 of 30 patients). In 24 patients, serum calcitonin levels showed a 50% or greater decrease from baseline that was maintained for at least 4 weeks; 16 patients showed a similar reduction in serum carcinoembryonic antigen levels. The most common adverse events were diarrhea (70%), rash (67%), fatigue (63%), and nausea (63%). Conclusion In this study, vandetanib demonstrated durable objective partial responses and disease control with a manageable adverse event profile. These results demonstrate that vandetanib may provide an effective therapeutic option in patients with advanced hereditary MTC, a rare disease for which there has been no effective therapy." @default.
• W2109833554 created "2016-06-24" @default.
• W2109833554 creator A5005775817 @default.
• W2109833554 creator A5019200558 @default.
• W2109833554 creator A5021663086 @default.
• W2109833554 creator A5039439529 @default.
• W2109833554 creator A5041250553 @default.
• W2109833554 creator A5044579003 @default.
• W2109833554 creator A5046671975 @default.
• W2109833554 creator A5052187410 @default.
• W2109833554 creator A5064660108 @default.
• W2109833554 creator A5074651462 @default.
• W2109833554 date "2010-02-10" @default.
• W2109833554 modified "2023-10-16" @default.
• W2109833554 title "Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer" @default.
• W2109833554 cites W1847774702 @default.
• W2109833554 cites W1971197406 @default.
• W2109833554 cites W1990171304 @default.
• W2109833554 cites W2019869717 @default.
• W2109833554 cites W2044761914 @default.
• W2109833554 cites W2062316437 @default.
• W2109833554 cites W2070767967 @default.
• W2109833554 cites W2083005649 @default.
• W2109833554 cites W2096993465 @default.
• W2109833554 cites W2101151768 @default.
• W2109833554 cites W2111060860 @default.
• W2109833554 cites W2112475888 @default.
• W2109833554 cites W2118559000 @default.
• W2109833554 cites W2125212831 @default.
• W2109833554 cites W2125916043 @default.
• W2109833554 cites W2139248078 @default.
• W2109833554 cites W2159075642 @default.
• W2109833554 cites W2160863198 @default.
• W2109833554 cites W2163840257 @default.
• W2109833554 cites W2222530102 @default.
• W2109833554 cites W2246590687 @default.
• W2109833554 doi "https://doi.org/10.1200/jco.2009.23.6604" @default.
• W2109833554 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2834392" @default.
• W2109833554 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20065189" @default.
• W2109833554 hasPublicationYear "2010" @default.
• W2109833554 type Work @default.
• W2109833554 sameAs 2109833554 @default.
• W2109833554 citedByCount "469" @default.
• W2109833554 countsByYear W21098335542012 @default.
• W2109833554 countsByYear W21098335542013 @default.
• W2109833554 countsByYear W21098335542014 @default.
• W2109833554 countsByYear W21098335542015 @default.
• W2109833554 countsByYear W21098335542016 @default.
• W2109833554 countsByYear W21098335542017 @default.
• W2109833554 countsByYear W21098335542018 @default.
• W2109833554 countsByYear W21098335542019 @default.
• W2109833554 countsByYear W21098335542020 @default.
• W2109833554 countsByYear W21098335542021 @default.
• W2109833554 countsByYear W21098335542022 @default.
• W2109833554 countsByYear W21098335542023 @default.
• W2109833554 crossrefType "journal-article" @default.
• W2109833554 hasAuthorship W2109833554A5005775817 @default.
• W2109833554 hasAuthorship W2109833554A5019200558 @default.
• W2109833554 hasAuthorship W2109833554A5021663086 @default.
• W2109833554 hasAuthorship W2109833554A5039439529 @default.
• W2109833554 hasAuthorship W2109833554A5041250553 @default.
• W2109833554 hasAuthorship W2109833554A5044579003 @default.
• W2109833554 hasAuthorship W2109833554A5046671975 @default.
• W2109833554 hasAuthorship W2109833554A5052187410 @default.
• W2109833554 hasAuthorship W2109833554A5064660108 @default.
• W2109833554 hasAuthorship W2109833554A5074651462 @default.
• W2109833554 hasBestOaLocation W21098335542 @default.
• W2109833554 hasConcept C121608353 @default.
• W2109833554 hasConcept C126322002 @default.
• W2109833554 hasConcept C143998085 @default.
• W2109833554 hasConcept C170493617 @default.
• W2109833554 hasConcept C197934379 @default.
• W2109833554 hasConcept C2777387746 @default.
• W2109833554 hasConcept C2778570526 @default.
• W2109833554 hasConcept C2778822529 @default.
• W2109833554 hasConcept C2779134260 @default.
• W2109833554 hasConcept C2779438470 @default.
• W2109833554 hasConcept C2779984678 @default.
• W2109833554 hasConcept C2780120053 @default.
• W2109833554 hasConcept C2780333294 @default.
• W2109833554 hasConcept C2993294228 @default.
• W2109833554 hasConcept C42362537 @default.
• W2109833554 hasConcept C526584372 @default.
• W2109833554 hasConcept C71924100 @default.
• W2109833554 hasConcept C90924648 @default.
• W2109833554 hasConceptScore W2109833554C121608353 @default.
• W2109833554 hasConceptScore W2109833554C126322002 @default.
• W2109833554 hasConceptScore W2109833554C143998085 @default.
• W2109833554 hasConceptScore W2109833554C170493617 @default.
• W2109833554 hasConceptScore W2109833554C197934379 @default.
• W2109833554 hasConceptScore W2109833554C2777387746 @default.
• W2109833554 hasConceptScore W2109833554C2778570526 @default.
• W2109833554 hasConceptScore W2109833554C2778822529 @default.
• W2109833554 hasConceptScore W2109833554C2779134260 @default.
• W2109833554 hasConceptScore W2109833554C2779438470 @default.
• W2109833554 hasConceptScore W2109833554C2779984678 @default.
• W2109833554 hasConceptScore W2109833554C2780120053 @default.
• W2109833554 hasConceptScore W2109833554C2780333294 @default.

• next